Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
74.98
-1.71 (-2.23%)
At close: Jan 8, 2026, 4:00 PM EST
75.01
+0.03 (0.04%)
After-hours: Jan 8, 2026, 7:01 PM EST
Kymera Therapeutics Stock Forecast
Stock Price Forecast
The 23 analysts that cover Kymera Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $105.35, which forecasts a 40.50% increase in the stock price over the next year. The lowest target is $52 and the highest is $138.
Price Target: $105.35 (+40.50%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Kymera Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 9 | 10 | 12 | 12 |
| Buy | 7 | 8 | 9 | 9 | 11 | 11 |
| Hold | 2 | 1 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 17 | 18 | 19 | 23 | 24 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jan 6, 2026 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $80 → $117 | Strong Buy | Maintains | $80 → $117 | +56.04% | Dec 22, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $70 → $103 | Buy | Maintains | $70 → $103 | +37.37% | Dec 16, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Maintains $65 → $110 | Buy | Maintains | $65 → $110 | +46.71% | Dec 11, 2025 |
| Mizuho | Mizuho | Buy Maintains $81 → $120 | Buy | Maintains | $81 → $120 | +60.04% | Dec 11, 2025 |
Financial Forecast
Revenue This Year
55.88M
from 47.07M
Increased by 18.71%
Revenue Next Year
49.78M
from 55.88M
Decreased by -10.91%
EPS This Year
-3.55
from -2.98
EPS Next Year
-3.79
from -3.55
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 110.3M | 105.0M | ||||
| Avg | 55.9M | 49.8M | ||||
| Low | 38.2M | 9.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 134.2% | 87.9% | ||||
| Avg | 18.7% | -10.9% | ||||
| Low | -18.8% | -82.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.91 | -3.14 | ||||
| Avg | -3.55 | -3.79 | ||||
| Low | -3.78 | -5.89 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.